Literature DB >> 17032660

Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass.

Y J Oh1, J H Lee, S B Nam, J K Shim, J H Song, Y L Kwak.   

Abstract

BACKGROUND: Chronic treatment with renin-angiotensin system (RAS) antagonists frequently causes deleterious hypotension during anaesthesia. We compared the effects of angiotensin II receptor antagonists (ARA) and angiotensin-converting enzyme inhibitors (ACEI) on neurohormonal levels and haemodynamics during cardiopulmonary bypass (CPB).
METHODS: Forty-four patients undergoing mitral valvular surgery who were treated with either ARA (ARA group, n=14) or ACEI (ACEI group, n=15) over 12 weeks or who were not treated with any RAS antagonist (control group, n=15) were enrolled. The plasma levels of epinephrine, norepinephrine, arginine vasopressin (AVP) and angiotensin II, and haemodynamic variables were measured before (T1) and 15 min after (T2) the start of CPB, before aortic unclamping (T3) and at skin closure (T4). Mean arterial pressure (MAP) was maintained above 60 mm Hg with phenylephrine administration during CPB.
RESULTS: The plasma epinephrine, norepinephrine, AVP and angiotensin II levels increased during CPB in all groups. Compared with the control group, the AVP level was lower at T1 in the ARA group and at T2 in the ARA and ACEI groups. The angiotensin II level was higher at T1, T2 and T3 in ARA group compared with ACEI and control groups. There were no significant differences in the epinephrine and norepinephrine levels among the three groups. The amount of administered phenylephrine during CPB was greater and MAP was lower in the ARA group compared with the ACEI and control groups.
CONCLUSIONS: Chronic ARA treatment resulted in more profound hypotension than ACEI treatment during CPB, and this may be associated with the blockade of angiotensin II receptors by ARA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032660     DOI: 10.1093/bja/ael268

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome.

Authors:  Michael W Manning; Mary Cooter; Joseph Mathew; John Alexander; Eric Peterson; T Bruce Ferguson; Renato Lopes; Mihai Podgoreanu
Journal:  Ann Thorac Surg       Date:  2017-01-25       Impact factor: 4.330

2.  Renal hemodynamics and oxygenation during experimental cardiopulmonary bypass in sheep under total intravenous anesthesia.

Authors:  Roger G Evans; Naoya Iguchi; Andrew D Cochrane; Bruno Marino; Sally G Hood; Rinaldo Bellomo; Peter R McCall; Clive N May; Yugeesh R Lankadeva
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-12-11       Impact factor: 3.619

3.  DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.

Authors:  Jessica R Wilson; Erica M Garner; Mona Mashayekhi; Scott A Hubers; Claudia E Ramirez Bustamante; Scott Jafarian Kerman; Hui Nian; Cyndya A Shibao; Nancy J Brown
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 9.897

4.  The Effect of Chronic Consumption of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists on Blood Pressure and Inotrope Consumption After Separation from Cardiopulmonary Bypass.

Authors:  Ebrahim Hassani; Alireza Mahoori; Nazli Karami; Asma Hassani; Leila Hassani
Journal:  Anesth Pain Med       Date:  2018-06-20

5.  Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.

Authors:  Sean van Diepen; Colleen M Norris; Yinggan Zheng; Jayan Nagendran; Michelle M Graham; Damaris Gaete Ortega; Derek R Townsend; Justin A Ezekowitz; Sean M Bagshaw
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.